According to a fairly recent news release from biopharmaceutical company Epygenix Therapeutics, Inc. ("Epygenix"), the company's therapy, EPX-200, received Orphan Drug designation from the FDA. Altogether, the therapy is designed…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
